About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

378040 studies
in
220 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/14/2021.

Safety and Immunogenicity of a Chlamydia Vaccine CTH522

Clinicaltrials.gov identifier NCT03926728

Recruitment Status Recruiting

First Posted April 24, 2019

Last update posted March 18, 2021

Study Description

Brief summary:

The present trial is a phase I, double-blind, parallel, randomised, and placebo-controlled trial of a chlamydia vaccine CTH522. Sixty-six subjects will be randomly assigned into six cohorts and are to receive four vaccination, in total of 12 trial visits. Cohorts A-D investigates CTH522-CAF01 administered IM in two doses (85 µg and 15 µg). Cohort E investigate CTH522-CAF09b also administered IM in one dose (85 µg). Cohort E is the placebo group. All subjects will receive a TO administration as a boost at Day 140 (4th vaccination). The TO boost will be non-adjuvanted CTH522 (12µg in each eye) or placebo. Nine subjects in each of cohorts A-E will receive the active boost (i.e. CTH522), three subjects will receive the placebo.

  • Condition or Disease:Trachoma
  • Intervention/Treatment: Biological: CTH522-CAF01 IM
    Biological: CTH522-CAF09b IM
    Biological: CTH522 ID
    Biological: CTH522 TO
    Biological: Placebo (Saline)
  • Phase: Phase 1
Detailed Description

This trial is a phase I, double-blind, parallel, randomised, and placebo-controlled trial of the chlamydia vaccine CTH522 in healthy adults. It is planned to randomly assign 66 subjects into six cohorts. Cohorts A-D investigate CTH522-CAF01 administered IM in two doses (85 μg and 15 μg). Cohort E investigates CTH522-CAF09b administered IM in one dose (85 μg). Cohort F is the placebo group. The enrolled subjects will complete 12 trial visits. All subjects in the active groups (cohort A-E) will receive three IM injections of the adjuvanted CTH522 and some (cohort B and C) will receive the non-adjuvanted CTH522 via the TO or ID route (given at the same time as the 2nd and 3rd IM vaccinations). All active groups will receive TO administration as a boost at Day 140 of either the non-adjuvanted CTH522 (12 μg in each eye) or placebo. - Cohort A will receive three IM vaccination of 85μg CTH522-CAF01. This cohort is divided into two groups: A1 will receive ID placebo at Day 28 + Day 112, and TO placebo at Day 140, while A2 will receive TO placebo at Day 28 + Day 112, and non-adjuvanted TO CTH522 boost at Day 140. - Cohort B will receive three IM vaccinations of 85 μg CTH522-CAF01. This cohort is divided into two groups: B1 will receive TO vaccination of the non-adjuvanted CTH522 at Day 28 and 112 and TO placebo at Day 140, while B2 will receive the same for Day 28 and 112, but non-adjuvanted TO CTH522 boost at Day 140. The two additional TO doses of CTH522 (12 μg in each eye) are administered in each eye. The rationale for this schedule is to investigate the impact of simultaneous TO administration of the antigen on the immunogenicity results. - Cohort C will receive three IM vaccinations of 85 μg CTH522-CAF01. This cohort is divided into two groups: C1 will receive ID vaccination of the non-adjuvanted 24 μg CTH522 at Day 28 and 112 and TO placebo at Day 140, while C2 will receive the same for Day 28 and 112, but TO 12 μg CTH522 boost in each eye at Day 140. The rationale for this schedule is to investigate the impact of simultaneous ID administration of the antigen on the immunogenicity results. - Cohort D will receive three IM vaccinations of 15 μg CTH522-CAF01. The rationale for the A and D cohorts is to investigate the impact of the two IM CTH522 doses on the immunogenicity results. - Cohort E will receive three IM vaccinations of 85 μg CTH522-CAF09b. The rationale for the A and E cohorts is to investigate the impact of the adjuvant on the immunogenicity results. - Cohort F will receive only placebo in the form of 0.9% NaCl saline (IM, ID and TO).

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 66 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Primary Purpose: Prevention
  • Official Title: A Phase I, Double-blind, Parallel, Randomised and Placebo-controlled Trial Investigating the Safety and Immunogenicity of a Chlamydia Vaccine, CTH522, in Healthy Adults
  • Actual Study Start Date: February 2020
  • Estimated Primary Completion Date: January 2022
  • Estimated Study Completion Date: March 2022
Arms and interventions
Arm Intervention/treatment
Experimental: Cohort A - 85µg CTH522-CAF01
Cohorts A will receive three IM vaccination of 85µg CTH522-CAF01. This cohort is divided into two groups: A1 will receive placebo at DAY 28 + Day 112 + Day 140, while A2 will receives placebo at Day 28 + Day 112, but non-adjuvanted TO CTH522 boost at Day 140.
Biological: CTH522-CAF01 IM
On-site reconstitution of IMPs is performed by mixing 85 microgram CTH522 with CAF01. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 ml polypropylene Luer-Lok™ syringe via 23-25-gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.

Biological: CTH522 TO
24 microgram CTH522 (12 microgram in each eye) TO administrations will be performed using a Gilson positive displacement pipette. The identity of vaccine will be known to the clinical site staff dispensing/administrating the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.

Biological: Placebo (Saline)
Placebo only given as IM, ID and TO
Experimental: Cohort B - 85µg CTH522-CAF01+ TO CTH522
Cohort B will receive three IM vaccination of 85 µg CTH522-CAF01. This cohort is divided into two groups: B1 will receive TO vaccination of the non-adjuvanted CTH522 at Day 28 + Day 112 and TO placebo at Day 140, while B2 will receive the same for Day 28 + Day 112, but non-adjuvanted TO CTH522 boost at Day 140. The two additional doses TO CTH522 (12µg) is administered in each eye. The rationale for this cohort is to investigate the impact of simultaneous TO administration of the antigen on the immunogenicity results obtained.
Biological: CTH522-CAF01 IM
On-site reconstitution of IMPs is performed by mixing 85 microgram CTH522 with CAF01. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 ml polypropylene Luer-Lok™ syringe via 23-25-gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.

Biological: CTH522 TO
24 microgram CTH522 (12 microgram in each eye) TO administrations will be performed using a Gilson positive displacement pipette. The identity of vaccine will be known to the clinical site staff dispensing/administrating the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.

Biological: Placebo (Saline)
Placebo only given as IM, ID and TO
Experimental: Cohort C - 85µg CTH522-CAF01+ID CTH522
Cohort C will receive three IM vaccination of 85 µg CTH522-CAF01. This cohort is divided into two groups: C1 will receive ID vaccination of the non-adjuvanted CTH522 at Day 28 + Day 12 and TO placebo at Day 140, while C2 will receive the same for Day 28 + Day 112, but TO CTH522 boost at Day 140. The two additional doses of non-adjuvanted CTH522 (24µg) is administered ID. The rationale for this cohort is to investigate the impact of simultaneous ID administration of the antigen on the immunogenicity results obtained.
Biological: CTH522-CAF01 IM
On-site reconstitution of IMPs is performed by mixing 85 microgram CTH522 with CAF01. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 ml polypropylene Luer-Lok™ syringe via 23-25-gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.

Biological: CTH522 ID
24 microgram CTH522 given ID is in the non-dominant deltoid muscle. ID with a 1 ml syringe via a 26-28 gauge needle using a NanoPass device or similar. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.

Biological: Placebo (Saline)
Placebo only given as IM, ID and TO
Experimental: Cohort D - 15µg CTH522-CAF01
Cohort D is the same as cohort A except that the dose for CTH522-CAF01 is 15µg.
Biological: CTH522-CAF01 IM
On-site reconstitution of IMPs is performed by mixing 85 microgram CTH522 with CAF01. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 ml polypropylene Luer-Lok™ syringe via 23-25-gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.

Biological: CTH522 TO
24 microgram CTH522 (12 microgram in each eye) TO administrations will be performed using a Gilson positive displacement pipette. The identity of vaccine will be known to the clinical site staff dispensing/administrating the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.

Biological: Placebo (Saline)
Placebo only given as IM, ID and TO
Experimental: Cohort E - 85µg CTH522-CAF09b
Cohort E is the same as cohort A except that the adjuvant is CAF09b and not CAF01. The rationale for the A, D and E cohorts is to investigate the impact of the CTH522 dose and adjuvant on the immunogenicity results.
Biological: CTH522-CAF09b IM
On-site reconstitution of IMPs is performed by mixing 85 microgram CTH522 with CAF09b. The preferred for IM is in the non-dominant deltoid muscle. IM injection will be performed with a 1-2 ml polypropylene Luer-Lok™ syringe via 23-25-gauge needle. The identity of the injected trial vaccine will be known to the clinical site staff dispensing and/or injecting the trial vaccine to the subject and by the unblinded trial monitor. The identity of the trial vaccine administered will remain unknown to the subject during the trial.

Biological: Placebo (Saline)
Placebo only given as IM, ID and TO
Placebo Comparator: Cohort F - Placebo
Cohort F will receive only placebo in form of 0.9% NaCl saline.
Biological: Placebo (Saline)
Placebo only given as IM, ID and TO
Outcome Measures
  • Primary Outcome Measures: 1. Local injection reactions [ Time Frame: Visit 2 (Day 0) to Visit 12 (Day 238) ]
    Local injection site reactions after intramuscular and intradermal vaccination
  • 2. Local ocular reactions [ Time Frame: Visit 2 (Day 0) to Visit 12 (Day 238) ]
    Local ocular reactions after topical ocular vaccination
  • 3. Systemic reactions [ Time Frame: Visit 2 (Day 0) to Visit 12 (Day 238) ]
    Systemic reactions after vaccinations
  • Secondary Outcome Measures: 1. Secondary - immunogenicity [ Time Frame: Visit 2 (Day 0) to Visit 12 (Day 238); except for Visit 10 (Day 143) ]
    Seroconversion for anti-CTH522 IgG at any time points after vaccinations of CTH522
  • Other Outcome Measures: 1. Exploratory - immunogenicity [ Time Frame: Visit 2 (Day 0) to Visit 12 (Day 238); except for Visit 3 (Day 14) for ocular strip ]
    Systemic and ocular antibodies: cell-mediated immune response, antibody responses measured by T- and B-cell Elispot, serum neutralising antibodies against serovars D-G. Isolation and characterisation of CTH522-antigen-specific memory B-cells in the systemic compartments (dependent on the elicited specific memory T- and B-cell numbers)
Eligibility Criteria
  • Ages Eligible for Study: 18 to 45 Years (Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: Yes
Criteria

Inclusion Criteria:

IC1: Healthy males and females between 18-45 years old on the day of the first vaccination
IC2: Has been properly informed about the trial and signed the consent form IC3: Is willing
and likely to comply with trial procedures IC4: Is prepared to grant authorised persons
access to his/her trial-related medical record IC5: Is willing to use acceptable
contraceptive measures during the trial (two weeks before and two weeks after the trial).
Heterosexually active female capable of becoming pregnant must agree to use hormonal
contraception, intrauterine device, intrauterine hormonereleasing system, or to complete
abstinence from at least two weeks before the first vaccination until at least two weeks
after the last. Complete abstinence (defined as refraining from heterosexual intercourse)
must be in line with the preferred and usual lifestyle of the subject. Periodic abstinence
(e.g. calendar, ovulation, symptothermal, post-ovulation methods), withdrawal and
progestogen-only oral hormonal contraception where inhibition of ovulation is not the
primary mode of action are not acceptable methods of contraception

Exclusion criteria:

EX1: Is positive for C. trachomatis via urine PCR or has a known history of C. trachomatis
EX2: Is positive for gonorrhoea via urine PCR test, or HIV, hepatitis B/C, syphilis via
blood tests EX3: Has a significant active disease such as cardiac, liver, immunological,
neurological, psychiatric or clinically significant abnormality of haematological or
biochemical parameters EX4: Has BMI ≥ 35 kg/m2 EX5: Is currently participating in another
clinical trial with an investigational or noninvestigational drug or device, or was treated
with an investigational drug within 28 days before the first vaccination EX6: Has received,
or plans to receive, any immunisation within 14 days of the start of the trial or during
the trial immunisations EX7: Is currently receiving treatment with systemic
immunosuppressive agents. Topical steroids are allowed unless applied to the IM or ID
injection site EX8: Has a condition which in the opinion of the investigator is not
suitable for participation in the trial EX9: Is known or confirmed to have an allergy to
any of the vaccine constituents EX10: Is unable to refrain from the use of contact lenses.
Contact lenses should be avoided two days before TO administration and for seven days later
(longer if any ongoing local eye AE) EX11: Has any evident ocular disease upon
ophthalmoscopic exam at screening or any medical history of ocular disease that, in the
opinion of the investigator, may impact the subject's participation in the trial EX12: Is
pregnant (positive pregnancy test) or breastfeeding or not willing to use contraception
during the trial EX13: Has confirmed a history of pelvic inflammatory disease or
significant gynaecological diseases

Contacts and Locations
Contacts

Contact: Lina S Stoey, MPH +4532683193 LSST@ssi.dk

Locations

United Kingdom
NIHR Imperial Center for Translational and Experimental Medicine
London

Sponsors and Collaborators

Statens Serum Institut

Imperial College London

Investigators

Study Director: Alvaro Borges, MD Statens Serum Institut

Principal Investigator: Katrina Pollock, MD Imperial Clinical Tesearch Facility Hammersmith Hospital

More Information
  • Responsible Party: Statens Serum Institut
  • ClinicalTrials.gov Identifier: NCT03926728 History of Changes
  • Other Study ID Numbers: CHLM-02
  • First Posted: April 24, 2019 Key Record Dates
  • Last Update Posted: March 18, 2021
  • Last Verified: March 2021
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by Statens Serum Institut: CTH522
    C. Trachomatis
    Chlamydia
  • Additional relevant MeSH terms: Chlamydia Infections Trachoma